Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by tamarindo1 on Oct 22, 2021 3:34pm

I Wonder

I wonder if Dr McFarland  has ever had any second thoughts or regrets about her involvement with Theralase.
Comment by Infinity on Oct 22, 2021 3:56pm
Tamarindo, That makes it two of us wondering if TLT management is fumbling with the Ball??
Comment by Gman620 on Oct 22, 2021 5:13pm
With a new CEO, and people that quit, I start wondering if anyone is managing the trials at the level needed to ensure results. You would at least expect a "new patient enrolled" message every now and then, or one of those 'we've added another clinic" happy news announcements. It's way to quiet.
Comment by Longholder99 on Oct 22, 2021 8:43pm
Its always quiet. Until it isnt. Been here seemingly forever. With American ICUs chock full of anti vaxxers. Ontario taking in the anti vaxxers from Saskatchewan. We are lucky elective procedures like ours are happening at all in these windows between waves. Still holding. Not selling. We will see what we will see. Sooner than later I hope.
Comment by CancerSlayer on Oct 22, 2021 10:33pm
  Fortunately, this trial has been expedited to a certain extent with their fast track designation.  A BTD would certainly add to that & further demonstrate proof of efficacy.  Cancer care, however, is not elective & outpatient cancer trials should be ongoing.  Hopefully, more word is getting out in the US...a BTD would certainly bolster our presence.  More than ...more  
Comment by patience69 on Oct 22, 2021 10:39pm
Always the optomist but it would seem that a delay in a newsletter would be good. Could the extra month or so possibly put us in position to apply for btd?  Maybe otherwise we hear nothing about it until 2022!!!
Comment by Oilminerdeluxe on Oct 23, 2021 12:52am
A few more patients have a check up in nov-dec, if I a not mistaken. Might be a good thing to have them done before a new update.
Comment by socksnblonds642 on Oct 23, 2021 9:22am
Well put CS. BTD does seem to be the path and so far the data we do have seems to be very positive. Albeit early days WRT trial info. Very much looking forward to the next trial report when the data is available. 
Comment by jmm1228 on Oct 23, 2021 1:02pm
And, in five weeks the 1st Quarter numbers will be posted. Then the mid-December Annual where we'll get a look at the mental acuity of our ancient CEO. Hopefully he will tell us he is ready to turn the reins over to someone who can do more than assemble assets - do what he is supposed to do, exploit them for the benefit of all stakeholders. As I dream on I do so knowing that bad ones do end.
Comment by jmm1228 on Oct 23, 2021 1:09pm
Previous message posted to wrong board.
Comment by skys1 on Oct 22, 2021 4:11pm
I know someone who has spoken to her and at least one of her grad students on several occasions. She supposedly is satisfied with TLT. However, she is a very intelligent woman so maybe that should be taken with a  "grain of salt, as it would be very foolish of her to publickly say she wasn't satisfied with the job TLT is doing, but a least on the outside she is content with TLT.
Comment by enriquesuave on Oct 22, 2021 4:30pm
Skys check your messages 
Comment by StevenBirch on Oct 22, 2021 5:12pm
I might be a cockeyed optimist but I just don't see how they have dropped the ball.  In Phase I they had a small problem with screening, for UUTUC, and fixed it. Phase I was stopped early on good results. In Phase II they had the dosing problem and by all accounts fixed that. We wait on the data which is out of their control, they can't speed that up. So is their 'ineptness' ...more  
Comment by socksnblonds642 on Oct 23, 2021 9:12am
I too remain optimistic and hopeful. I agree with your sentiments. I don't need info until there is trial data. For now no news is good news. The trials can't be rushed and the numbers can't be fabricated. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250